



# NGS AND LYSOSOMAL DYSFUNCTION

## NOVEL MUTATIONS ASSOCIATED WITH NEURODEGENERATIVE DISORDERS



**Marisa Encarnação**, Francisca Coutinho, Liliana Matos, Lisbeth Silva,  
Diogo Ribeiro, Célia Nogueira, Laura Vilarinho, and Sandra Alves

LSD diagnosis can be difficult due to considerable clinical overlap and variability



Multiple samples and test are often required before a diagnosis is reached (is time consuming)



High-throughput sequencing is cost and time effective

Custom-targeted panel for LSD genes



Identification of disease-causing mutations in LSD




Unidade de Rastreio Neonatal  
Porto



Rare diseases: desperately seeking diagnosis




# Our NGS Panel




# Our NGS Workflow

## Sample Preparation and Sequencing (Illumina MiSeq) (2-3 days)

## Analysis Software (1-2 days)



# RESULTS-TRAINING SET

Total number of studied patients  18

Number of diagnosed patients  7

	Gene	Mutation	Impact on Protein	Molecular Diagnosis
Novel Mutations	<b>MFSD8</b>	p.G455R/G455P	YES	Neuronal Ceroid Lipofuscinosis 7
	<b>NAGLU</b>	p.D312N/D312N	YES	Mucopolysaccharidosis type IIIB
	<b>GM2A</b>	p.G104Gfs*14/G104Gfs*14	YES	GM2 Gangliosidosis AB variant*
	<b>GALC</b>	p.Y205X/Y205X	YES	Krabbe
	<b>NPC1</b>	p.V505G/V562V	Unclear	
Described	<b>NPC1</b>	p.A3T/N961S	YES	Niemann-Pick type C
	<b>MAN2B1</b>	p.802Qfs*128/802Qfs*128	YES	Alpha-mannosidosis



# Patients with Neurodegenerative LSD

**Mutation** p.G455R in *MFSD8*



**CLN7 protein (unclear function)  
Lysosome membrane mainly**

**CLN7-** Late infantile form of NCL

*There are at least 14 different genes associated with NCL*

**Mutation** p.G104Gfs14 in *GM2A*



**GM2 activator protein (necessary for substrate solubilisation)  
Lysosome lumen**

**GM2 Gangliosidosis - AB variant**

# Patients with Neurodegenerative LSD

**Mutation** p.G455R in *MFSD8*



**CLN7 protein (unclear function)  
Lysosome membrane mainly**

**CLN7-** Late infantile form of NCL

*There are at least 14 different genes associated with NCL*

**Mutation** p.G104Gfs14 in *GM2A*




**GM2 activator protein (necessary for substrate solubilisation)  
Lysosome lumen**

**GM2 Gangliosidosis - AB variant**

*Clinically and biochemically undistinguishable of the other two variants (Sandhoff and Tay-Sachs)*


**Our NGS approach allowed a rapid and precise diagnosis in these patients**

# CLN7 protein



## Future perspectives

- Expand the present NGS panel in order to include more genes involved in the Lysosomal Function.
- For the cases where a diagnostic is not reached even after using the extended panel perform other NGS analysis (WES and WGS).



For further informations about these two customized gene panels, please contact Dr. Sandra Alves: [sandra.alves@insa.min-saude.pt](mailto:sandra.alves@insa.min-saude.pt)

# Acknowledgments

## DGH - INSA

### Unidade Investigação e Desenvolvimento

Sandra Alves

Francisca Coutinho

Liliana Matos

### Unidade de Rastreio Neonatal

Laura Vilarinho

Célia Nogueira

Lisbeth Silva

Paulo Gaspar

Diogo Ribeiro

### Unidade de Tecnologia e Inovação

Luís Vieira

Catarina Silva

Sílvia Duarte

Joana Mendonça

## External Collaborators

Souad Ouesleti - Service de Biochimie, CHU Farhat Hached (Tunisia)

Maria Teresa Cardoso – CHSJ

Esmeralda Martins – CHP

Sheela Nampoothiri – Amrita

Institute Of Medical Sciences (India)

## Funding



PROGRAMA OPERACIONAL REGIONAL DO NORTE 2014-2020



**DESVENDAR - DEScobrir, VENcer as Doenças rARas" (NORTE-01-0246-FEDER-000014). NORTE 2020**